Last year, pharmaceutical manufacturers significantly increased the amount of money they spent promoting new drugs, which they do mainly by sending sales representatives to visit physicians in their offices. However, two years ago there was an average of 640 such visits per representative, whereas last year that figure fell to 501. So the additional promotion must have been counterproductive, making physicians less willing to receive visits by pharmaceutical sales representatives.
Most physicians who agree to receive a visit from a pharmaceutical sales representative will see that representative more than once during a given year if true, most weakens the argument.